{
  "id": "ee1ab3f45c96475d",
  "title": "STAT+: Ocular\u2019s experimental eye drug beats low dose of Regeneron\u2019s Eylea in late-stage trial",
  "description": "Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.",
  "content": "Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/?utm_campaign=rss",
  "published_at": "2026-02-17T12:00:00+00:00",
  "fetched_at": "2026-02-18T00:30:07.542614+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Ocular\u2019s experimental eye drug beats low dose of Regeneron\u2019s Eylea in late-stage trial",
    "description": "Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.",
    "url": "https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/?utm_campaign=rss",
    "published": "2026-02-17T12:00:00+00:00",
    "source": "STAT"
  }
}